Although the healthcare industry has a long way to go before PGx testing for DPYD and other genes becomes widespread, it’s encouraging that regulatory bodies and professional organizations are making recommendations and raising awareness among healthcare providers. The post Drug-Gene Testing: Key to Safer Cancer Treatment appeared first on MedCity News.
Healthtech companies have to navigate a maze of complex regulations, prove their financial model, and win over multiple stakeholders. Finding the right balance between patient protection and innovation is crucial. The post Barriers and Pathways to Healthtech Adoption in Clinical Practice appeared first on MedCity News.
Saturday is the day that nearly 24 million customers can start purchasing health plans on healthcare.gov and the state-run Obamacare exchanges. Higher prices and uncertainty await many of those shoppers. Average premiums are expected to more than double. The directors who manage marketplace enrollment in states including Maryland, California, Pennsylvania, and Idaho told me and my colleague Julie Appleby that people are wondering how they’ll scrape together hundreds — or even thousands — of dollars more next year to pay for these…
Why has there been so little progress against the rate of osteoporotic fractures and the associated morbidity and mortality? The deaths are real, the pain and suffering are real — and almost all of us have witnessed it. And, of course, the cost to our health system, $57 billion per year, is real. The post…
Robert F. Kennedy Jr.’s rise to become secretary of the Department of Health and Human Services has some concerned that anti-vaccine policies are coming. If the nation’s top public health agency pulls support of vaccination, other healthcare stakeholders will need to step up to fill the vaccine messaging void. The post How the Health Sector…
The Phase 2 failure in major depressive disorder marks the second time in a little more than a year that Neurocrine Biosciences has reported a drug licensed from Takeda Pharmaceutical fell short in the clinic. Last year, a different drug from this partnership failed a mid-stage test in schizophrenia. The post Neurocrine Bio Drug Licensed…
What are the practices that we have normalized that future generations will criticize us for? Sachin Jain, CEO of SCAN Health Plan, is perhaps the leading truth teller in health care who also runs a real health care organization. I had a really fun but serious interview with Sachin about what health care people are…
At the end of the day, when patients and doctors are unable to effectively engage in health care conversations, the quality of care and patient health suffer, resulting in rising U.S. healthcare costs, lower quality of care, and unhealthy patients. The post Rekindling the Doctor, Patient Relationship appeared first on MedCity News.
GLP-1s have proven to be highly effective for weight loss but pose significant cost challenges for employers, according to a recent panel of experts at MedCity INVEST. The post Are GLP-1s Worth the Hype? appeared first on MedCity News.
The non-responder gap matters for two reasons: First, patients who are in an advanced stage of cancer lose valuable time in ineffective therapy. Second, it increases the cost of therapy and resources for both patients and the broader healthcare ecosystem. The post An AI Driven Approach to Address the Non-Responder Gap in Radiopharmaceutical Therapy appeared…